Table 2 Clinically important pain outcomes by age and dose group
|  | ≥30% Pain relief, n (%) | ≥50% Pain relief, n (%) | Endpoint pain score ≤3, n (%)* | ||
|---|---|---|---|---|---|
| Â | BOCF | LOCF | BOCF | LOCF | Â |
18-64 years | Â | Â | Â | Â | Â |
   Placebo | 153 (35.7) | 163 (38.1) | 94 (22.0) | 98 (22.9) | 111 (25.9) |
   Pregabalin 150 mg/d | 72 (39.3) | 74 (40.4) | 45 (24.6) | 46 (25.1) | 50 (27.3) |
   Pregabalin 300 mg/d | 109 (48.0) | 120 (52.9) | 73 (32.2) | 82 (36.1) | 92 (40.5) |
   Pregabalin 600 mg/d | 199 (51.3) | 236 (60.8) | 153 (39.4) | 179 (46.1) | 170 (43.8) |
65-74 years | Â | Â | Â | Â | Â |
   Placebo | 73 (24.6) | 80 (26.9) | 47 (15.8) | 51 (17.2) | 57 (19.2) |
   Pregabalin 150 mg/d | 45 (34.6) | 48 (36.9) | 31 (23.8) | 32 (24.6) | 34 (26.2) |
   Pregabalin 300 mg/d | 56 (44.8) | 68 (54.4) | 38 (30.4) | 46 (36.8) | 43 (34.4) |
   Pregabalin 600 mg/d | 109 (54.0) | 132 (65.3) | 83 (41.1) | 99 (49.0) | 91 (45.0) |
≥75 years |  |  |  |  |  |
   Placebo | 39 (21.0) | 42 (22.6) | 22 (11.8) | 23 (12.4) | 24 (12.9) |
   Pregabalin 150 mg/d | 40 (35.7) | 46 (41.1) | 28 (25.0) | 32 (28.6) | 36 (32.1) |
   Pregabalin 300 mg/d | 43 (30.1) | 64 (44.8) | 30 (21.0) | 42 (29.4) | 38 (26.6) |
   Pregabalin 600 mg/d | 24 (33.8) | 41 (57.7) | 18 (25.4) | 32 (45.1) | 35 (49.3) |